


RESEARCH REPORT



Immuno-Oncology Diagnostics

Market Forecasts for Immuno-Oncology Diagnostics

Including Executive/Consultant Guides and Customized Forecasting/Analysis.
2022 to 2026





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

| | | |
|-------|--|----|
| 1 | Market Guides | 21 |
| 1.1 | Situation Analysis | 22 |
| 1.2 | Guide for Executives and Marketing Staff | 24 |
| 1.3 | Guide for Investment Analysts and Management Consultants | 25 |
| 2 | Introduction and Market Definition | 26 |
| 2.1 | What are Immuno-Oncology Diagnostics? | 27 |
| 2.2 | Immuno-oncology – the looming cure | 29 |
| 2.2.1 | Immuno-oncology Diagnostics Takes a Leading Role..... | 31 |
| 2.3 | Market Definition | 32 |
| 2.3.1 | Market Size | 32 |
| 2.3.2 | Currency | 32 |
| 2.3.3 | Years | 32 |
| 2.4 | Methodology | 33 |
| 2.4.1 | Authors | 33 |
| 2.4.2 | Sources | 33 |
| 2.5 | Perspective: Healthcare and the IVD Industry | 34 |
| 2.5.1 | Global Healthcare Spending | 34 |
| 2.5.2 | Spending on Diagnostics | 35 |
| 2.5.3 | Important Role of Insurance for Diagnostics..... | 37 |
| 3 | Immunotherapy – Guide to Immune Technologies | 38 |
| 3.1 | The Immune System | 39 |
| 3.1.1 | Innate immune system | 40 |

| | | |
|---------|---|----|
| 3.1.1.1 | Surface barriers | 41 |
| 3.1.1.2 | Inflammation | 42 |
| 3.1.1.3 | Complement system | 42 |
| 3.1.1.4 | Cellular barriers | 43 |
| 3.1.1.5 | Natural killer cells | 44 |
| 3.1.2 | Adaptive immune system | 45 |
| 3.1.2.1 | Lymphocytes..... | 45 |
| 3.1.2.2 | Killer T cells | 46 |
| 3.1.2.3 | Helper T cells | 48 |
| 3.1.2.4 | Gamma delta T cells | 49 |
| 3.1.2.5 | B lymphocytes and antibodies | 49 |
| 3.1.3 | Tumor immunology – the immune surveillance system | 51 |
| 3.2 | Immuno Oncology Diagnostics | 53 |
| 3.2.1 | Checkpoint Assays | 53 |
| 3.2.1.1 | Outlook for Checkpoint Assays..... | 57 |
| 3.2.2 | Cytokine Assays | 58 |
| 3.2.2.1 | Outlook for Cytokine Assays | 59 |
| 3.2.3 | Genomic Germline..... | 59 |
| 3.2.3.1 | Outlook for Genomic Germline | 60 |
| 3.2.4 | Genomic Tumour | 60 |
| 3.2.4.1 | Outlook for Genomic Tumour..... | 63 |
| 3.2.5 | Tumor Microenvironment | 64 |
| 3.2.5.1 | Outlook for Tumor Microenvironment | 65 |
| 3.2.6 | Others..... | 65 |
| 3.2.6.1 | Outlook for Other Diagnostics..... | 65 |

| | | |
|--------|--|----|
| 4 | Industry Overview | 66 |
| 4.1 | Players in a Dynamic Market | 67 |
| 4.1.1 | Academic Research Lab..... | 68 |
| 4.1.2 | Diagnostic Test Developer | 68 |
| 4.1.3 | Genomic Instrumentation Supplier | 68 |
| 4.1.4 | Cell Separation and Viewing Instrumentation Supplier | 69 |
| 4.1.5 | Pharmaceutical/Reagent Supplier..... | 69 |
| 4.1.6 | Independent Testing Lab..... | 69 |
| 4.1.7 | Public National/regional lab | 70 |
| 4.1.8 | Hospital lab..... | 70 |
| 4.1.9 | Physician Lab | 70 |
| 4.1.10 | Audit Body | 71 |
| 4.1.11 | Certification Body | 71 |
| 5 | Market Trends..... | 73 |
| 5.1 | Factors Driving Growth | 74 |
| 5.1.1 | Outcome potential | 74 |
| 5.1.2 | Companion Diagnostics | 75 |
| 5.1.3 | Funding | 75 |
| 5.1.4 | Technology Environment | 75 |
| 5.1.5 | Target Solutions | 76 |
| 5.2 | Factors Limiting Growth | 77 |
| 5.2.1 | Complex Role of Diagnostics | 77 |
| 5.2.2 | Clinical Trials Role..... | 78 |
| 5.2.3 | Protocols..... | 78 |
| 5.3 | Diagnostic Technology Development | 79 |

| | | |
|-------|--|-----|
| 5.3.1 | Combinations - Issues and Complexity | 79 |
| 5.3.2 | Shifting Role of Diagnostics..... | 81 |
| 5.3.3 | Multiplexing and Foundation One..... | 82 |
| 5.3.4 | The Disruption Dynamic | 83 |
| 5.3.5 | The Race for Biomarkers | 83 |
| 5.3.6 | The Next Five Years..... | 84 |
| 6 | Cancer Immuno-Oncology Diagnostics Recent Developments | 85 |
| 6.1 | Recent Developments – Importance and How to Use This Section | 86 |
| 6.1.1 | Importance of These Developments..... | 86 |
| 6.1.2 | How to Use This Section..... | 86 |
| 6.2 | OncoHost Expands Prophet Platform Research | 86 |
| 6.3 | Protein-Based Liquid Biopsy Panel Assesses TME..... | 87 |
| 6.4 | Oncimmune Announces Sixfold Revenue Increase..... | 90 |
| 6.5 | Mayo Clinic, Personalis Ink Collaboration..... | 92 |
| 6.6 | Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes | 93 |
| 6.7 | Qiagen, OncXerna Close Companion Dx Development Deal..... | 96 |
| 6.8 | Natera Test to Guide Therapy for Bladder Cancer | 97 |
| 6.9 | Veracyte Halio Acquisition to Boost Immuno-oncology Activity | 100 |
| 6.10 | Freenome Eyes New Dx Possibilities..... | 102 |
| 6.11 | Oncocyte Data has Potential as Immunotherapy Response Predictor | 105 |
| 6.12 | OncoDNA use HalioDx to Expand into North America | 109 |
| 6.13 | Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq Assay . | 110 |
| 6.14 | Qiagen Expands Immuno-Oncology Portfolio | 110 |
| 6.15 | Immune Profiling System Redirected to Fight COVID-19..... | 111 |
| 6.16 | IncellDx Awarded PD-L1 Detection Patent | 114 |

| | | |
|------|---|-----|
| 6.17 | FDA Approves CDx for Trastuzumab | 114 |
| 6.18 | Promega Nabs CE Mark for Microsatellite Instability IVD | 116 |
| 6.19 | ArcherDx partners with AstraZeneca for Immuno-Oncology | 117 |
| 6.20 | Germline Results Guides Precision Therapy | 118 |
| 6.21 | Agilent PD-L1 Assay Gets FDA Approval..... | 122 |
| 6.22 | Bayer, OrigiMed Form Companion Diagnostic Development Alliance | 122 |
| 6.23 | Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy..... | 123 |
| 6.24 | SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures | 124 |
| 6.25 | Biocare Medical Launches 7 Novel IVD Antibodies..... | 125 |
| 6.26 | Oncocyte to Acquire Insight Genetics for \$12M | 126 |
| 6.27 | Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm | 128 |
| 6.28 | Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment..... | 129 |
| 6.29 | Generex to Merge with NuGenerex Immuno-Oncology..... | 130 |
| 6.30 | Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop Companion Diagnostics for Cancer Therapies | 131 |
| 6.31 | Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative Breast Cancer | 133 |
| 6.32 | Icon Acquires MolecularMD | 133 |
| 7 | Profiles of Key Immuno-oncology Companies | 135 |
| 7.1 | 10x Genomics, Inc..... | 136 |
| 7.2 | Abbott Diagnostics | 137 |
| 7.3 | AccuraGen Inc..... | 139 |
| 7.4 | Adaptive Biotechnologies..... | 140 |
| 7.5 | Aethlon Medical..... | 141 |
| 7.6 | Agena Bioscience, Inc..... | 142 |

| | | |
|------|--|-----|
| 7.7 | Agilent/Dako | 144 |
| 7.8 | Anchor Dx | 146 |
| 7.9 | ANGLE plc | 147 |
| 7.10 | ApoCell, Inc. | 148 |
| 7.11 | ARUP Laboratories..... | 149 |
| 7.12 | Asuragen..... | 151 |
| 7.13 | AVIVA Biosciences | 153 |
| 7.14 | Baylor Miraca Genetics Laboratories..... | 154 |
| 7.15 | Beckman Coulter Diagnostics | 155 |
| 7.16 | BGI Genomics Co. Ltd | 158 |
| 7.17 | Bioarray Genetics..... | 160 |
| 7.18 | Biocartis | 161 |
| 7.19 | Biocept, Inc..... | 162 |
| 7.20 | Biodesix Inc. | 163 |
| 7.21 | BioFluidica | 164 |
| 7.22 | BioGenex..... | 165 |
| 7.23 | BioIVT | 167 |
| 7.24 | Biolidics Ltd..... | 168 |
| 7.25 | bioMérieux Diagnostics..... | 169 |
| 7.26 | Bioneer Corporation | 172 |
| 7.27 | Bio-Rad Laboratories, Inc. | 174 |
| 7.28 | Bio-Reference Laboratories..... | 176 |
| 7.29 | Bio-Techne | 177 |
| 7.30 | Bioview | 178 |
| 7.31 | Bolidics..... | 179 |

| | | |
|------|-------------------------------------|-----|
| 7.32 | Boreal Genomics..... | 180 |
| 7.33 | Bristol-Myers Squibb..... | 181 |
| 7.34 | Burning Rock..... | 183 |
| 7.35 | Cancer Genetics..... | 184 |
| 7.36 | Cardiff Oncology | 186 |
| 7.37 | Caris Molecular Diagnostics..... | 187 |
| 7.38 | Castle Biosciences, Inc. | 188 |
| 7.39 | CellMax Life | 189 |
| 7.40 | Cepheid (Danaher) | 190 |
| 7.41 | Charles River Laboratories..... | 192 |
| 7.42 | Chronix Biomedical..... | 193 |
| 7.43 | Circulogene | 194 |
| 7.44 | Clinical Genomics | 195 |
| 7.45 | Cynvenio..... | 196 |
| 7.46 | Cytolumina Technologies Corp..... | 197 |
| 7.47 | CytoTrack..... | 198 |
| 7.48 | Datar Cancer Genetics Limited | 199 |
| 7.49 | Diagnologix LLC..... | 200 |
| 7.50 | Diasorin S.p.A. | 201 |
| 7.51 | Enzo Biochem | 203 |
| 7.52 | Epic Sciences..... | 205 |
| 7.53 | Epigenomics AG..... | 206 |
| 7.54 | Eurofins Scientific | 207 |
| 7.55 | Exosome Diagnostics | 209 |
| 7.56 | Exosome Sciences..... | 210 |

| | | |
|------|---------------------------------|-----|
| 7.57 | Fabric Genomics..... | 211 |
| 7.58 | Fluidigm Corp | 212 |
| 7.59 | Fluxion Biosciences..... | 213 |
| 7.60 | Foundation Medicine | 214 |
| 7.61 | Freenome..... | 215 |
| 7.62 | FUJIFILM Wako Diagnostics..... | 216 |
| 7.63 | GeneFirst Ltd. | 217 |
| 7.64 | Genetron Holdings | 218 |
| 7.65 | GenomOncology..... | 219 |
| 7.66 | GILUPI Nanomedizin..... | 220 |
| 7.67 | Grail, Inc. | 221 |
| 7.68 | Guardant Health | 222 |
| 7.69 | HalioDx | 223 |
| 7.70 | HansaBiomed | 224 |
| 7.71 | HeiScreen | 225 |
| 7.72 | Helomics..... | 226 |
| 7.73 | Horizon Discovery | 227 |
| 7.74 | HTG Molecular Diagnostics | 229 |
| 7.75 | iCellate | 230 |
| 7.76 | Illumina | 231 |
| 7.77 | Incell Dx..... | 232 |
| 7.78 | Inivata..... | 233 |
| 7.79 | Integrated Diagnostics | 234 |
| 7.80 | Invitae Corporation..... | 235 |
| 7.81 | Invivogen | 237 |

| | | |
|-------|---|-----|
| 7.82 | Invivoscribe | 238 |
| 7.83 | Janssen Diagnostics | 239 |
| 7.84 | MDNA Life SCIENCES, Inc. | 240 |
| 7.85 | MDx Health | 241 |
| 7.86 | Menarini Silicon Biosystems..... | 242 |
| 7.87 | Millipore Sigma | 243 |
| 7.88 | Miltenyi Biotec | 244 |
| 7.89 | MIODx..... | 245 |
| 7.90 | miR Scientific..... | 246 |
| 7.91 | Molecular MD | 247 |
| 7.92 | MyCartis | 248 |
| 7.93 | Myriad Genetics/Myriad RBM | 249 |
| 7.94 | NantHealth, Inc. | 250 |
| 7.95 | Natera | 252 |
| 7.96 | NeoGenomics | 254 |
| 7.97 | New Oncology | 256 |
| 7.98 | NGeneBio..... | 257 |
| 7.99 | Novogene Bioinformatics Technology Co., Ltd. | 259 |
| 7.100 | Oncocyte | 261 |
| 7.101 | OncoDNA | 262 |
| 7.102 | Ortho Clinical Diagnostics | 263 |
| 7.103 | Oxford Nanopore Technologies..... | 264 |
| 7.104 | Panagene | 265 |
| 7.105 | Perkin Elmer | 266 |
| 7.106 | Personal Genome Diagnostics..... | 268 |

| | | |
|-------|------------------------------------|-----|
| 7.107 | Personalis | 269 |
| 7.108 | Precipio | 270 |
| 7.109 | PrecisionMed..... | 271 |
| 7.110 | Promega..... | 272 |
| 7.111 | Qiagen..... | 274 |
| 7.112 | Rarecells SAS | 276 |
| 7.113 | RareCyte | 277 |
| 7.114 | Roche Molecular Diagnostics | 278 |
| 7.115 | Screecell..... | 280 |
| 7.116 | Sense Biodetection..... | 281 |
| 7.117 | Serametrix..... | 282 |
| 7.118 | Siemens Healthineers | 283 |
| 7.119 | Silicon Biosystems | 285 |
| 7.120 | simfo GmbH..... | 286 |
| 7.121 | Singlera Genomics Inc. | 287 |
| 7.122 | Singulomics..... | 288 |
| 7.123 | SkylineDx | 290 |
| 7.124 | Stratos Genomics..... | 291 |
| 7.125 | Sysmex Inostics | 292 |
| 7.126 | Tempus Labs, Inc. | 293 |
| 7.127 | Thermo Fisher Scientific Inc. | 294 |
| 7.128 | Thrive Earlier Detection..... | 297 |
| 7.129 | Todos Medical..... | 298 |
| 7.130 | Volition | 299 |
| 7.131 | Vortex Biosciences..... | 300 |

| | | |
|-------|--|-----|
| 8 | The Global Market for Immuno-Oncology Diagnostics..... | 301 |
| 8.1 | Global Market Overview by Country..... | 302 |
| 8.1.1 | Table – Global Market by Country..... | 302 |
| 8.1.2 | Chart - Global Market by Country..... | 303 |
| 8.2 | Global Market by Assay Type - Overview..... | 304 |
| 8.2.1 | Table – Global Market by Assay Type | 304 |
| 8.2.2 | Chart – Global Market by Assay Type – Base/Final Year Comparison..... | 305 |
| 8.2.3 | Chart – Global Market by Assay Type – Base Year | 306 |
| 8.2.4 | Chart – Global Market by Assay Type – End Year..... | 307 |
| 8.2.5 | Chart – Global Market by Assay Type – Share by Year | 308 |
| 8.2.6 | Chart – Global Market by Assay Type – Segments Growth..... | 309 |
| 8.3 | Global Market by Technology - Overview | 310 |
| 8.3.1 | Table – Global Market by Technology | 310 |
| 8.3.2 | Chart – Global Market by Technology – Base/Final Year Comparison | 311 |
| 8.3.3 | Chart – Global Market by Technology – Base Year..... | 312 |
| 8.3.4 | Chart – Global Market by Technology – End Year..... | 313 |
| 8.3.5 | Chart – Global Market by Technology – Share by Year | 314 |
| 8.3.6 | Chart – Global Market by Technology – Segments Growth | 315 |
| 8.4 | Global Market by Customer - Overview..... | 316 |
| 8.4.1 | Table – Global Market by Customer..... | 316 |
| 8.4.2 | Chart – Global Market by Customer – Base/Final Year Comparison..... | 317 |
| 8.4.3 | Chart – Global Market by Customer – Base Year | 318 |
| 8.4.4 | Chart – Global Market by Customer – End Year | 319 |
| 8.4.5 | Chart – Global Market by Customer – Share by Year | 320 |
| 8.4.6 | Chart – Global Market by Customer – Segments Growth..... | 321 |

| | | |
|--------|---|-----|
| 9 | Global Immuno-Oncology Diagnostic Markets – By Application..... | 322 |
| 9.1 | Checkpoint..... | 323 |
| 9.1.1 | Table Checkpoint – by Country..... | 323 |
| 9.1.2 | Chart - Checkpoint Growth..... | 324 |
| 9.2 | Cytokine..... | 325 |
| 9.2.1 | Table Cytokine – by Country..... | 325 |
| 9.2.2 | Chart - Cytokine Growth..... | 326 |
| 9.3 | Germline Genetic..... | 327 |
| 9.3.1 | Table Germline Genetic – by Country..... | 327 |
| 9.3.2 | Chart - Germline Genetic Growth..... | 328 |
| 9.4 | Genetic Tumor..... | 329 |
| 9.4.1 | Table Genetic Tumor – by Country..... | 329 |
| 9.4.2 | Chart - Genetic Tumor Growth..... | 330 |
| 9.5 | Tumor Microenvironment..... | 331 |
| 9.5.1 | Table Tumor Microenvironment – by Country..... | 331 |
| 9.5.2 | Chart – Tumor Microenvironment Growth..... | 332 |
| 9.6 | Other..... | 333 |
| 9.6.1 | Table Other – by Country..... | 333 |
| 9.6.2 | Chart - Other Growth..... | 334 |
| 10 | Global Immuno-Oncology Diagnostic Markets – By Technology..... | 335 |
| 10.1 | NGS..... | 336 |
| 10.1.1 | Table NGS – by Country..... | 336 |
| 10.1.2 | Chart - NGS Growth..... | 337 |
| 10.2 | PCR..... | 338 |
| 10.2.1 | Table PCR – by Country..... | 338 |

| | | |
|--------|--|-----|
| 10.2.2 | Chart - PCR Growth | 339 |
| 10.3 | Fish/IHC..... | 340 |
| 10.3.1 | Table Fish/IHC – by Country | 340 |
| 10.3.2 | Chart - Fish/IHC Growth..... | 341 |
| 10.4 | Chem/IA..... | 342 |
| 10.4.1 | Table Chem/IA – by Country | 342 |
| 10.4.2 | Chart - Chem/IA Growth..... | 343 |
| 10.5 | Other Technology | 344 |
| 10.5.1 | Table Other Technology – by Country..... | 344 |
| 10.5.2 | Chart – Other Technology Growth..... | 345 |
| 11 | Global Immuno-Oncology Diagnostic Markets – By Customer | 346 |
| 11.1 | Pharma..... | 347 |
| 11.1.1 | Table Pharma – by Country | 347 |
| 11.1.2 | Chart - Pharma Growth..... | 348 |
| 11.2 | Clinic..... | 349 |
| 11.2.1 | Table Clinic – by Country | 349 |
| 11.2.2 | Chart - Clinic Growth..... | 350 |
| 11.3 | Other Customer Genetic..... | 351 |
| 11.3.1 | Table Other Customer – by Country | 351 |
| 11.3.2 | Chart - Other Customer Growth..... | 352 |
| 12 | Appendices..... | 353 |
| 12.1 | FDA Cancer Drug Approvals by Year | 354 |
| 12.2 | Clinical Trials Started 2010 to 2016 | 355 |
| 12.3 | Prevalence of Cancer Treatments..... | 356 |
| 12.4 | United States Medicare System: 2022 Clinical Laboratory Fees Schedule..... | 357 |

Table of Tables

| | |
|--|-----|
| Table 1 List of Cancers by Mortality | 30 |
| Table 2 Overview of Innate and Adaptive Immunity | 40 |
| Table 3 FDA Approved Monoclonal Antibodies in Cancer treatment | 54 |
| Table 4 FDA Approved Companion diagnostics in Cancer treatment | 61 |
| Table 5 Market Players by Type | 67 |
| Table 6 Five Factors Driving Growth | 74 |
| Table 7 Three Factors Limiting Growth..... | 77 |
| Table 8 - Global Market by Region..... | 302 |
| Table 9 Global Market by Assay Type | 304 |
| Table 10 Global Market by Technology | 310 |
| Table 11 Global Market by Customer | 316 |
| Table 12 Checkpoint by Country | 323 |
| Table 13 Cytokine by Country | 325 |
| Table 14 Germline Genetic by Country | 327 |
| Table 15 Genetic Tumor by Country..... | 329 |
| Table 16 Tumor Microenvironment by Country | 331 |
| Table 17 Other by Country | 333 |
| Table 18 NGS by Country..... | 336 |
| Table 19 PCR by Country | 338 |
| Table 20 Fish/IHC by Country | 340 |
| Table 21 Chem/IA by Country | 342 |
| Table 22 Other Technology by Country | 344 |

Table 23 Pharma by Country.....347

Table 24 Clinic by Country.....349

Table 25 Other Customer by Country.....351

Table 26 2022 Clinical Lab Fee Schedule.....357

Table of Figures

| | |
|---|-----|
| Figure 1 Cancer Death Rates – USA, CDC | 29 |
| Figure 2 World Health Care Spending | 35 |
| Figure 3 The Lab Test Pie | 36 |
| Figure 4 Helper T Cell Roles | 48 |
| Figure 5 Antibody Diagram | 50 |
| Figure 6 Macrophages attack a Cancer Cell | 51 |
| Figure 7 The Tumour Micro Environment..... | 64 |
| Figure 8 Comparing IO Diagnostic and Traditional Testing..... | 81 |
| Figure 9 Growth rates of IO Diagnostic Technologies..... | 84 |
| Figure 10 Global Market Density Chart | 303 |
| Figure 11 Global Market by Assay Type - Base vs. Final..... | 305 |
| Figure 12 Global Market by Assay Type Base Year | 306 |
| Figure 13 Global Market by Assay Type End Year..... | 307 |
| Figure 14 Assay Type Share by Year | 308 |
| Figure 15 Assay Type Segments Growth..... | 309 |
| Figure 16 Global Market by Technology - Base vs. Final | 311 |
| Figure 17 Global Market by Technology Base Year..... | 312 |
| Figure 18 Global Market by Technology End Year | 313 |
| Figure 19 Technology Share by Year | 314 |
| Figure 20 Technology Segments Growth | 315 |
| Figure 21 Global Market by Customer - Base vs. Final..... | 317 |
| Figure 22 Global Market by Customer Base Year | 318 |

| | |
|--|-----|
| Figure 23 Global Market by Customer End Year | 319 |
| Figure 24 Customer Share by Year | 320 |
| Figure 25 Customer Segments Growth..... | 321 |
| Figure 26 Checkpoint Growth | 324 |
| Figure 27 Cytokine Growth | 326 |
| Figure 28 Germline Genetic Growth | 328 |
| Figure 29 Genetic Tumor Growth..... | 330 |
| Figure 30 Tumor Microenvironment Growth | 332 |
| Figure 31 Other Growth..... | 334 |
| Figure 32 NGS Growth | 337 |
| Figure 33 PCR Growth | 339 |
| Figure 34 Fish/IHC Growth..... | 341 |
| Figure 35 Chem/IA Growth..... | 343 |
| Figure 36 Other Technology Growth | 345 |
| Figure 37 Pharma Growth..... | 348 |
| Figure 38 Clinic Growth | 350 |
| Figure 39 Other Customer Growth..... | 352 |
| Figure 40 FDA Cancer Drug Approvals by Year | 354 |
| Figure 41 Clinical Trials for Immunotherapy by Year | 355 |
| Figure 42 Pie Chart of Prevalence of Cancer Treatments | 356 |